Veterinary Medicines

CANIGEN CEP

Authorised
  • Canine distemper virus, strain Lederle, Live
  • Canine parvovirus, strain Cornell 780916, Live
  • Canine adenovirus 2, strain Manhattan, Live
Download as PDF

Product identification

Medicine name:
CANIGEN CEP
Active substance:
  • Canine distemper virus, strain Lederle, Live
  • Canine parvovirus, strain Cornell 780916, Live
  • Canine adenovirus 2, strain Manhattan, Live
Target species:
  • Dog
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Canine distemper virus, strain Lederle, Live
    3.00
    log10 50% cell culture infectious dose
    /
    1.00
    Dose
  • Canine parvovirus, strain Cornell 780916, Live
    5.00
    log10 50% cell culture infectious dose
    /
    1.00
    Dose
  • Canine adenovirus 2, strain Manhattan, Live
    4.00
    log10 50% cell culture infectious dose
    /
    1.00
    Dose
Pharmaceutical form:
  • Suspension for injection
Withdrawal period by route of administration:
  • Subcutaneous use
    • Dog
      • Unspecified
        0
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI07AD02
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Italy
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Virbac
Marketing authorisation date:
Manufacturing sites for batch release:
  • Virbac
Responsible authority:
  • Ministry Of Health
Authorisation number:
This information is not available for this product.
Date of authorisation status change: